Radiation and immunotherapy join forces against mesothelioma

NCT ID NCT04926948

Completed Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This early-phase trial is testing whether combining a precise type of radiation (SBRT) with immunotherapy can safely treat pleural mesothelioma, a rare cancer of the lung lining. About 20 adults with confirmed mesothelioma will receive both treatments. The main goal is to see if the combination is feasible and does not cause too many severe side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: immunotherapy (immune checkpoint inhibitor) and stereotactic body radiation therapy (SBRT)
What this could lead to: If this works, it could point toward a more effective, less toxic treatment combination for mesothelioma.
What could go wrong: This is a very early phase 1 trial with only 20 participants, so it is primarily testing safety and feasibility, not effectiveness. The combination may cause unexpected side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLEURAL MESOTHELIAL NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pleural mesothelioma pleural mesothelioma pleural neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLEURAL MESOTHELIAL NEOPLASM

Contacts and locations

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.